"Recent studies have shown new antibody drugs to slow cognitive decline among people with early-onset Alzheimer's - a critical finding, given that the disease as of now has no cure. CBS News chief medical correspondent Dr. Jon LaPook visits Washington University School of Medicine in St. Louis, which is conducting important research into treating the disease before symptoms arise. The clinical trials involve the 1 to 2 percent of people with Alzheimer's who are genetically predisposed to developing dementia."
"CBS News chief medical correspondent Dr. Jon LaPook visits Washington University School of Medicine in St. Louis, which is conducting important research into treating the disease before symptoms arise. The clinical trials involve the 1 to 2 percent of people with Alzheimer's who are genetically predisposed to developing dementia. He also talks with philanthropist Bill Gates, who has already donated $300 million to support Alzheimer's research."
New antibody drugs have been shown to slow cognitive decline in people with early-onset Alzheimer's. Research at Washington University School of Medicine in St. Louis is testing treatments administered before symptoms appear. The clinical trials enroll the 1 to 2 percent of people with Alzheimer's who carry genetic predispositions to dementia. The trials aim to intervene pre-symptomatically to alter disease progression. Bill Gates has donated $300 million to accelerate Alzheimer's research. The disease currently has no cure, so therapies that slow decline represent important advances toward earlier and potentially more effective interventions.
Read at Cbsnews
Unable to calculate read time
Collection
[
|
...
]